JP2010523492A5 - - Google Patents

Download PDF

Info

Publication number
JP2010523492A5
JP2010523492A5 JP2010501048A JP2010501048A JP2010523492A5 JP 2010523492 A5 JP2010523492 A5 JP 2010523492A5 JP 2010501048 A JP2010501048 A JP 2010501048A JP 2010501048 A JP2010501048 A JP 2010501048A JP 2010523492 A5 JP2010523492 A5 JP 2010523492A5
Authority
JP
Japan
Prior art keywords
phenyl
ethyl
methyl
hydroxypyrrolidin
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010501048A
Other languages
English (en)
Japanese (ja)
Other versions
JP5416085B2 (ja
JP2010523492A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/056317 external-priority patent/WO2008121496A1/en
Publication of JP2010523492A publication Critical patent/JP2010523492A/ja
Publication of JP2010523492A5 publication Critical patent/JP2010523492A5/ja
Application granted granted Critical
Publication of JP5416085B2 publication Critical patent/JP5416085B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010501048A 2007-03-30 2008-03-07 下痢型および交替型過敏性腸症候群の処置のためのカッパ−オピエートアゴニスト Expired - Fee Related JP5416085B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92084107P 2007-03-30 2007-03-30
US60/920,841 2007-03-30
PCT/US2008/056317 WO2008121496A1 (en) 2007-03-30 2008-03-07 Kappa-opiate agonists for the treatment of diarrhea-predominant and alternating irritable bowel syndrome

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013101705A Division JP2013173790A (ja) 2007-03-30 2013-05-13 下痢型および交替型過敏性腸症候群の処置のためのカッパ−オピエートアゴニスト

Publications (3)

Publication Number Publication Date
JP2010523492A JP2010523492A (ja) 2010-07-15
JP2010523492A5 true JP2010523492A5 (enExample) 2011-05-12
JP5416085B2 JP5416085B2 (ja) 2014-02-12

Family

ID=39795494

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010501048A Expired - Fee Related JP5416085B2 (ja) 2007-03-30 2008-03-07 下痢型および交替型過敏性腸症候群の処置のためのカッパ−オピエートアゴニスト
JP2013101705A Pending JP2013173790A (ja) 2007-03-30 2013-05-13 下痢型および交替型過敏性腸症候群の処置のためのカッパ−オピエートアゴニスト

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013101705A Pending JP2013173790A (ja) 2007-03-30 2013-05-13 下痢型および交替型過敏性腸症候群の処置のためのカッパ−オピエートアゴニスト

Country Status (19)

Country Link
US (2) US7960429B2 (enExample)
EP (3) EP2136801B1 (enExample)
JP (2) JP5416085B2 (enExample)
KR (2) KR101263225B1 (enExample)
CN (2) CN102641265A (enExample)
AU (1) AU2008232954A1 (enExample)
BR (1) BRPI0809651A2 (enExample)
CA (1) CA2682608A1 (enExample)
CY (1) CY1113317T1 (enExample)
DK (1) DK2136801T3 (enExample)
ES (1) ES2393815T3 (enExample)
HR (1) HRP20120798T1 (enExample)
IL (1) IL201226A0 (enExample)
MX (1) MX2009010409A (enExample)
PL (1) PL2136801T3 (enExample)
PT (1) PT2136801E (enExample)
RU (1) RU2441655C2 (enExample)
SI (1) SI2136801T1 (enExample)
WO (1) WO2008121496A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2136801B1 (en) * 2007-03-30 2012-08-29 Tioga Pharmaceuticals, Inc. Kappa-opiate agonists for the treatment of diarrhea-predominant and alternating irritable bowel syndrome
US9303027B2 (en) 2010-07-19 2016-04-05 Dr. Reddy's Laboratories Ltd. Kappa opioid receptor agonists
US20140179727A1 (en) 2012-12-14 2014-06-26 Trevi Therapeutics, Inc. Methods for treating pruritus
US8987289B2 (en) 2012-12-14 2015-03-24 Trevi Therapeutics, Inc. Methods for treating pruritus
US8637538B1 (en) 2012-12-14 2014-01-28 Trevi Therapeutics, Inc. Methods for treatment of pruritis
ES2955693T3 (es) 2012-12-24 2023-12-05 Neurogastrx Inc Métodos para el tratamiento de trastornos del tracto GI
WO2015200369A1 (en) 2014-06-24 2015-12-30 Neurogastrx, Inc. Prodrugs of metopimazine
JP6410641B2 (ja) 2015-03-04 2018-10-24 ローム株式会社 ワイヤレス送電装置、異物検出方法、充電器
WO2018035046A1 (en) 2016-08-15 2018-02-22 President And Fellows Of Harvard College Treating infections using idsd from proteus mirabilis
EP3558300B1 (en) 2016-12-21 2021-11-24 Tioga Pharmaceuticals, Inc. Solid pharmaceutical formulations of asimadoline
WO2019122361A1 (en) 2017-12-22 2019-06-27 Dr. August Wolff Gmbh & Co. Kg Arzneimittel Asimadoline for use in treating pulmonary diseases, vascular diseases, and sepsis
EP3826635A4 (en) 2018-07-23 2022-04-27 Trevi Therapeutics, Inc. TREATMENT OF CHRONIC COUGH, SHORTNESS OF BREATH AND DYSPNEA
EP4087569A4 (en) 2020-01-10 2024-01-24 Trevi Therapeutics, Inc. METHODS OF ADMINISTRATION OF NALBUPHINE
AU2021236662A1 (en) * 2020-03-18 2022-11-10 Cara Therapeutics, Inc. Oligosaccharide formulations of kappa opioid receptor agonists
US10836757B1 (en) 2020-04-02 2020-11-17 Neurogastrx, Inc. Polymorphic forms of metopimazine
EP3932390A1 (en) 2020-07-02 2022-01-05 Dr. August Wolff GmbH & Co. KG Arzneimittel Topical gel formulation containing asimadoline
JP7464744B2 (ja) * 2020-10-20 2024-04-09 セトラスホールディングス株式会社 診療支援装置、診療支援方法、診療支援プログラム及び診療支援システム
WO2022155332A1 (en) * 2021-01-13 2022-07-21 Blue Therapeutics, Inc. Methods of treating irritable bowel syndrome

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4192883A (en) * 1976-04-09 1980-03-11 Pierre Fabre, S.A. Amides of pyrrolidinoethylamine which can be used in lung therapy
FR2421891A1 (fr) 1977-10-17 1979-11-02 Fabre Sa Pierre Obtention industrielle d'amides de la pyrrolidine ethyl amine
US4663343A (en) * 1985-07-19 1987-05-05 Warner-Lambert Company Substituted naphthalenyloxy-1,2-diaminocyclohexyl amide compounds
US4889860A (en) * 1985-09-23 1989-12-26 Nova Pharmaceutical Corporation Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists
US4760069A (en) * 1985-09-23 1988-07-26 Nova Pharmaceutical Corporation Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists
GB8601796D0 (en) * 1986-01-24 1986-02-26 Zambeletti Spa L Compounds
EP0330467A1 (en) 1988-02-23 1989-08-30 Glaxo Group Limited Heterocyclic compounds
DE4034785A1 (de) 1990-11-02 1992-05-07 Merck Patent Gmbh 1-(2-arylethyl)-pyrrolidine
US5232978A (en) * 1988-12-23 1993-08-03 Merck Patent Gesellschaft Mit Beschrankter Haftung 1-(2-arylethyl)-pyrrolidines
DE3935371A1 (de) 1988-12-23 1990-07-05 Merck Patent Gmbh Stickstoffhaltige ringverbindungen
US5389686A (en) * 1989-02-20 1995-02-14 Jouveinal Sa Analgesic properties of fedotozine
DE3916663A1 (de) * 1989-05-23 1990-11-29 Bayer Ag Substituierte (chinolin-2-yl-methoxy)phenyl-acyl-sulfonamide und -cyanamide, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
US5232266A (en) * 1989-07-24 1993-08-03 Mork William J Upholstered article of furniture with interchangeable seating module
GB8926560D0 (en) 1989-11-24 1990-01-17 Zambeletti Spa L Pharmaceuticals
AU641955B2 (en) 1989-11-24 1993-10-07 Dr. Lo Zambeletti S.P.A. N-acyl-substituted azacyclic compounds, processes for their preparation, and their use as pharmaceuticals
US5300687A (en) 1991-07-18 1994-04-05 Ortho Pharmaceutical Corporation Trifluoromethylbenzylphosphonates useful in treating osteoporosis
DE4215213A1 (de) 1992-05-09 1993-11-11 Merck Patent Gmbh Arylacetamide
DE4425071C2 (de) * 1994-07-15 1996-08-29 Degussa Verfahren zur Herstellung optisch aktiver Pyrrolidine mit hoher Enantiomerenreinheit
DE19523502A1 (de) * 1995-06-28 1997-01-02 Merck Patent Gmbh Kappa-Opiatagonisten für entzündliche Darmerkrankungen
DE19531464A1 (de) 1995-08-26 1997-02-27 Merck Patent Gmbh N-Methyl-N-[(1S-)-1-phenyl-2-((3S)-3-hydroxypyrrolidin 1-yl-)-ethyl]-2,2-diphenyl-acetamid
DK1021204T3 (da) * 1997-09-26 2006-05-08 Noven Pharma Bioadhæsive præparater og fremgangsmåder til topisk administration af aktive midler
US20010051181A1 (en) * 1997-12-22 2001-12-13 Van Osdol William W. Novel formulations for the transdermal administration of asimadoline
DE19827633A1 (de) * 1998-04-20 1999-10-21 Merck Patent Gmbh Verfahren zur Herstellung von enantiomerenreinem N-Methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamid
AU754740B2 (en) * 1998-06-30 2002-11-21 Takeda Chemical Industries Ltd. Pharmaceutical composition for the treatment of diabetes
JP2000080047A (ja) 1998-06-30 2000-03-21 Takeda Chem Ind Ltd 医 薬
DE19849650A1 (de) * 1998-10-29 2000-05-04 Merck Patent Gmbh Kappa-Opiatagonisten für die Behandlung des Irritable Bowel Syndroms (IBS)
ES2234523T3 (es) 1999-03-01 2005-07-01 Pfizer Products Inc. Acidos oxamicos que contienen ciano y sus derivados como ligandos de receptores tiroideos.
GB0015562D0 (en) 2000-06-23 2000-08-16 Pfizer Ltd Heterocycles
US20020025948A1 (en) * 2000-06-23 2002-02-28 Banks Bernard Joseph 3-azabicyclo[3.1.0]hexane derivatives useful in therapy
US6262062B1 (en) 2000-08-15 2001-07-17 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
US6846831B2 (en) * 2000-08-15 2005-01-25 Cpd, Llc Method of treating the syndrome of lipodystrophy
US6569449B1 (en) * 2000-11-13 2003-05-27 University Of Kentucky Research Foundation Transdermal delivery of opioid antagonist prodrugs
DE10116978A1 (de) 2001-04-05 2002-10-10 Merck Patent Gmbh Kappa-Opiatagonisten für die Behandlung von Erkrankungen der Blase
AU2002364517A1 (en) 2001-11-30 2003-06-17 Sepracor Inc. Tramadol analogs and uses thereof
CA2486000A1 (en) * 2002-05-17 2003-11-27 Merck Patent Gesellschaft Mit Beschraenkter Haftung Use of compounds that are effective as selective opiate receptor modulators
WO2004026819A2 (en) * 2002-09-18 2004-04-01 The Curators Of The University Of Missouri OPIATE ANALOGS SELECTIVE FOR THE delta-OPIOID RECEPTOR
DE10259245A1 (de) * 2002-12-17 2004-07-01 Merck Patent Gmbh Derivate des Asimadolins mit kovalent gebundenen Säuren
MXPA05010819A (es) * 2003-04-08 2006-03-30 Progenics Pharm Inc Uso de antagonistas de opioide perifericos, especialmente metilnaltrexona para tratar sindrome de intestino irritable.
ES2528631T3 (es) * 2003-04-08 2015-02-11 Progenics Pharmaceuticals, Inc. Formulaciones farmacéuticas que contienen metilnaltrexona
WO2005016244A2 (en) * 2003-06-13 2005-02-24 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
JP2007509865A (ja) * 2003-10-30 2007-04-19 ティオガ ファーマシュウティカルズ,インコーポレイテッド 神経障害の治療における選択的オピエート受容体調節物質の使用
AR057325A1 (es) * 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
EP2136801B1 (en) * 2007-03-30 2012-08-29 Tioga Pharmaceuticals, Inc. Kappa-opiate agonists for the treatment of diarrhea-predominant and alternating irritable bowel syndrome

Similar Documents

Publication Publication Date Title
JP2010523492A5 (enExample)
RU2009140042A (ru) Агонисты каппа-опиоидов для лечения синдрома раздраженного кишечника с преобладанием диареи и перемежающегося синдрома раздраженного кишечника
Trinkley et al. Medication management of irritable bowel syndrome
KR101323628B1 (ko) 용해성 결합제를 포함하는 대장 하제 조성물
JP2010518122A5 (enExample)
JP2009536176A5 (enExample)
JP2020517719A5 (enExample)
JP2010525084A5 (enExample)
JP2009280621A5 (enExample)
ES3009607T3 (en) Nk-1 antagonist compositions and methods for use in treating depression
JP2010522137A5 (enExample)
TW202341996A (zh) 用於治療腸胃疾病或病狀之神經活性類固醇
JP2019535760A5 (ja) ガボキサドールを用いた注意欠陥多動性障害(adhd)の治療方法
JP2012531402A5 (enExample)
JP2008533127A5 (enExample)
JP2011527687A5 (enExample)
Palaniyappan et al. Combining antidepressants: a review of evidence
McCarberg Overview and treatment of opioid-induced constipation
PT1359939E (pt) Composição e método para potenciar fármacos
JP2011519873A5 (enExample)
JP2020531543A (ja) アマンタジン組成物、その調製、および使用方法
JP2013032308A5 (enExample)
WO2023164387A1 (en) Neuroactive steroids for treatment of gastrointestinal diseases or conditions
HRP20171330T1 (hr) Postupak za proizvodnju i korištenje kopolimera natrijeve karboksimetil celuloze i gosipola
JP2019142774A (ja) 腸内環境改善剤